Duopharma (M) Sdn Bhd (DMSB) has secured a RM155.28 million contract from the Health Ministry to supply recombinant human insulin products and reusable insulin pens to government healthcare facilities.

DMSB is a wholly owned subsidiary of Duopharma Biotech Bhd, a publicly listed company with its controlling shareholder being government-linked investment fund Permodalan Nasional Bhd (PNB).

In a filing with Bursa Malaysia today, DMSB said...